Stock Analysis
Novavax, Inc. (NVAX) Stock Analysis
Novavax, Inc. (NVAX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Novavax, Inc. (NVAX) currently has an AIQ Score of —, indicating a — setup. Momentum is the strongest factor at 77/100. Risk is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NVAX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.53 |
| AIQ Score | — |
| Overall View | Unavailable |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.41B |
| P/E Ratio (TTM) | -18.53 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.19 |
| Revenue (Q3 FY2026) | $68.3M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 2.12 |
| Volume | 4.64M |
| 52-week range | $6.20-$13.39 |
| RSI 14 | 37.64 |
| 50-Day SMA | $10.54 |
| 200-Day SMA | $9.33 |
| Analyst Price Target | $8.00 |
| Next Earnings | Feb 25, 2027 |
NVAXNovavax, Inc.
Healthcare / Biotechnology
Latest quote
- Momentum77
- Value—
- Quality62
- Risk resilience38
- Sentiment—
NVAX Stock Analysis Summary
Novavax, Inc. (NVAX) currently has an AIQ Score of —, indicating a — setup. Momentum is the strongest factor at 77/100. Risk resilience is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a — regime, NVAX has AIQ Score of — with Momentum base of 77/100 and fading Risk resilience at 38/100. Wait for component alignment before adding exposure.
Momentum (77/100) leads while Risk resilience (38/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.68% stock move · NVAX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NVAX Bullish or Bearish Right Now?
NVAX currently has a unavailable overall setup. Momentum is the strongest factor at 77/100, while Risk Resilience is weakest at 38/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 77/100.
- - Risk Resilience is weak at 38/100.
- - Price is -8.66% below its 200-day SMA.
- - Analyst target implies -6.16% downside from the latest quote.
- - Technical consensus has more sell votes than buy votes (37 vs 6).
Current Consensus
NVAX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. NVAX's 14-day RSI is 37.64, which places the stock in a weaker momentum range. NVAX's beta is 2.12, indicating greater market sensitivity than the broad market.
What Changed in NVAX?
The largest recent change in NVAX is Quality moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the NVAX Outlook?
The current unavailable outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NVAX Decision Framework
Public evidence layers, setup checks, and risk context for Novavax, Inc..
Novavax, Inc. (NVAX) Stock Analysis
Novavax, Inc. has an AIQ Score of — in a — regime. Momentum is strongest at 77/100. Beta is 2.12, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NVAX is in a — AIQ regime with score —. |
| Signal Conflict | The primary conflict is that momentum leads at 77/100 while risk lags at 38/100. |
| Factor Evidence | Momentum 77/100 · Quality 62/100 · Risk 38/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 77/100.
Momentum is 77/100 and RSI (14) is 37.6.
NVAX is in a — regime at —.
Risk factor is 38/100 with beta 2.12 and annual volatility 73.62%.
Current conflict: momentum leads at 77/100 while risk lags at 38/100.
NVAX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NVAX Fundamentals
NVAX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NVAX Technical Analysis
NVAX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NVAX Stock Catalysts
Track NVAX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NVAX Dividend Analysis
NVAX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NVAX Financial Data
NVAX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NVAX Risk Analysis
NVAX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NVAX Stock News
NVAX stock news, market tone, recent headlines, and catalyst context.
NVAX vs Biotechnology Peers
Current peer cohort: NVAX · OCUL · OMER · ONC · ORKA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NVAX Current stock | — | — | 77/100 | 38/100 | 0.56 | 73.62% | Current |
| OCUL Ocular Therapeutix, Inc. | 38/100 | 41/100 | 34/100 | 36/100 | -0.45 | 76.10% | NVAX vs OCUL |
| OMER Omeros Corporation | 64/100 | 73/100 | 79/100 | 33/100 | 1.36 | 110.84% | NVAX vs OMER |
| ONC BeOne Medicines AG | 80/100 | 71/100 | 91/100 | 72/100 | 0.42 | 34.16% | NVAX vs ONC |
| ORKA Oruka Therapeutics, Inc. | 77/100 | — | 81/100 | 53/100 | 2.29 | 69.09% | NVAX vs ORKA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NVAX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NVAX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NVAX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NVAX Stock FAQ
What is NVAX stock price today?
Novavax, Inc.'s current stock price is $8.53. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NVAX bullish or bearish right now?
NVAX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NVAX's market cap?
NVAX's market cap is $1.41B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NVAX's current P/E ratio?
NVAX's current P/E ratio is -18.53 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NVAX's RSI?
NVAX's 14-day RSI is 37.64 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NVAX above its 50-day and 200-day moving averages?
NVAX is -19.09% from its 50-day SMA and -8.66% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NVAX's next earnings date?
NVAX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NVAX pay a dividend?
NVAX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.